Former Dexcel Pharma Analytical Chemist to Join Innocan Pharma LPT Pharmaceutical R&D Team as it is Moving Forward with the LPT Development
Israel and Calgary, Alberta--(Newsfile Corp. - July 12, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has appointed Nissim Vasilevski as Analytical Chemist. In this role, Mr. Vasilevski will join the team developing analytical methods to accelerate this critical development and validations of Innocan Pharma's liposome platform technology (LPT) product line, with a view to reaching human clinical trials and...
2022-07-12 3:37 AM EDT
Innocan Reports Positive Results from Recent Preclinical Trial on Epileptic Seizures On a Dog using LPT: "Since The Last LPT injection, Paco (dog) Has Not Had a Seizure for Over 10 weeks"
Israel and Calgary, Alberta--(Newsfile Corp. - July 6, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce positive results in a preclinical trial involving a dog with refractory (drug-resistant) epilepsy. In this trial, the dog was treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injections. The results demonstrated that the frequency and the intensity of the dog's epileptic seizures decreased...
2022-07-06 4:00 PM EDT
Innocan Reports Successful Preclinical Dog-Trial Results Regarding Pain Management: "It Was as If a New Dog Came into Our Lives"
Israel and Calgary, Alberta--(Newsfile Corp. - June 24, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce successful preclinical trials in dogs with osteoarthritis. A case entailing the clinical condition of Goody, an 8-year-old male mixed-breed dog, who was rescued in a terrible condition after he was found tied up with a very short leash, cachectic and wounded, was published. Goody suffers from severe osteoarthritis...
2022-06-24 4:00 PM EDT
Innocan Pharma Announces Filing of PCT Patent Application for Vaginal Atrophy Treatment
Israel and Calgary, Alberta--(Newsfile Corp. - June 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed a new PCT patent application entitled "Compositions for Treatment of Vaginal Atrophy" on June 12, 2022, claiming priority from a US provisional patent. Vaginal atrophy is a condition associated with loss of moisture, thinning, and inflammation of the vaginal walls, which can be associated with...
2022-06-17 4:00 PM EDT
Innocan Reports Successful Preliminary Trial Results Regarding Epilepsy in Dogs
Israel and Calgary, Alberta--(Newsfile Corp. - June 10, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the successful preliminary results of a small-scale efficacy trial in dogs with refractory (drug-resistant) epilepsy. In this initial phase, the dogs were treated with Innocan Pharma's LPT (CBD Loaded Liposome Platform) injection. The results demonstrate that these dogs had a decrease in the frequency of their...
2022-06-10 4:00 PM EDT
Innocan Pharma Announces Q1 2022 Results with 215% Increase in Cash Balance and 200% Increase in Working Capital
Israel and Calgary, Alberta--(Newsfile Corp. - May 30, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to report its financial results for the quarter ended March 31, 2022.First Quarter 2022 Financial and Operating Highlights:Cash balance at end of Q1-22 - USD 9.5M, in Q1-21 - USD 4.4M, an increase of approximately of 215% from corresponding quarter.Net loss for Q1-22 - USD 0.7M. Net loss in Q1-21 - USD 4.8M, a...
2022-05-30 4:00 PM EDT
Innocan Pharma Obtains Receipt for Final Base Shelf Prospectus
Israel and Calgary, Alberta--(Newsfile Corp. - May 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has filed and obtained a receipt for a final short form base shelf prospectus (the "Base Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada.The Base Shelf Prospectus allows Innocan to qualify the distribution of up to $100,000,000 of common...
2022-05-17 2:03 AM EDT
Innocan Pharma Announces the Successful Publication of a New Patent Application of Its New Sustained-Release (LPC) CBD Formulation
Israel and Calgary, Alberta--(Newsfile Corp. - May 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that an International Patent Application ("PCT") titled "Protein-bound Cannabinoid Formulations and Uses Thereof" was recently published and received the publication number WO 2022/070191 (the "Patent Application"), claiming priority from a US provisional application filed in October 2020.The Patent Application...
2022-05-11 3:00 AM EDT
Innocan Pharma's Compassionate Care Treatment for Dogs
Israel and Calgary, Alberta--(Newsfile Corp. - April 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is proud to announce the publication of a case report regarding its compassionate care liposomal-CBD formulation (Innocan's LPT platform) (the "Treatment"). The Treatment was administered to a 14-year-old dog suffering from severe cervical pain, hip and elbow osteoarthritis and testicular neoplasia. It was reported that the Treatment...
2022-04-29 3:00 AM EDT
Innocan Pharma's Case Report Accepted to the 25M Readers of Frontiers Veterinary Scientific Journal
Israel and Calgary, Alberta--(Newsfile Corp. - April 11, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to report the "accepted for publication" of a Case Report Article describing subcutaneously injected liposomal cannabidiol (CBD) formulation used as a compassion therapy for pain management in a dog. The final article will be published in the Frontiers Veterinary Scientific Journal, a leading and renowned journal with...
2022-04-11 4:00 PM EDT
Innocan Pharma Reports a Successful FDA-Required Characterization of Highly CBD-Loaded Liposome Platform
Israel and Calgary, Alberta--(Newsfile Corp. - March 28, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), is pleased to report the successful completion of Innocan's CBD Liposome drug-product physico-chemical characterization. Physico-chemical characterization is an important part of the application package to be submitted to the FDA. It is also a crucial milestone towards a potential submission of an Investigational New Drug Application...
2022-03-28 4:00 PM EDT
Innocan Pharma Reports a Positive Result from the Use of Its CBD LPT on a Dog Suffering from Osteoarthritis
Israel and Calgary, Alberta--(Newsfile Corp. - March 8, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that Innocan's CBD LPT injection provided as a treatment to a dog suffering from osteoarthritis of the hip and elbow joint (causing inability of the dog to walk and stand up, as well as intense pain and a low activity rate) led to a decrease in pain and improved activity and...
2022-03-08 4:00 PM EST
Former Beckman Coulter Dr. Eyal Kalo to join Innocan Pharma's Expanding R&D Team
Israel and Calgary, Alberta--(Newsfile Corp. - March 4, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the appointment of Dr. Eyal Kalo as Research and Development Project Manager. In this new role Dr. Eyal Kalo will coordinate internal and external R&D projects, assist in the development progress and manage the cross functional of Innocan's pharma projects. About Dr.Eyal KaloDr.Eyal Kalo earned his PhD from the...
2022-03-04 3:00 AM EST
Sony Ex-VP Dr. Kenji Kitatani to Join Innocan Pharma's Advisory Committee
Israel and Calgary, Alberta--(Newsfile Corp. - February 7, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce the addition of Dr. Kenji Kitatani, a leading global media business expert, and former Executive Officer of Sony Corporation, to Innocan pharma's Advisory Committee, as an advisor to the Asian markets.The popularity of CBD products in Japan is growing rapidly. Combined with the growing admiration to natural...
2022-02-07 4:36 PM EST
Innocan Pharma Announces Important Updates Regarding its LPT Platform Project and Commercialization Paths
Israel and Calgary, Alberta--(Newsfile Corp. - January 20, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to provide an update on its research into CBD loaded liposomes using Innocan's LPT platform. Innocan's core goal is to develop a technology that combines the advantages of two well-known drug and delivery system to create a novel drug product that can be used for vast array of diseases.
2022-01-20 3:00 AM EST
Innocan Pharma Announces the Inauguration of Its Drug Development Lab at Biohouse in the Hadassah Medical Center in Jerusalem
Israel and Calgary, Alberta--(Newsfile Corp. - January 17, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") is pleased to announce that it has inaugurated its first and new drug research and development lab at Biohouse Labs at Hadassah Medical Center in Jerusalem to accelerate the Company's liposome Platform Technology (LPT) development. The Company's development program is focused on improving and optimizing LPT characterization methods...
2022-01-17 4:00 PM EST
Innocan Pharma to Expand its LPT Platform to the Veterinary Field
Israel and Calgary, Alberta--(Newsfile Corp. - January 13, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce a second amendment (the "Amendment") to the research and license agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. ("Yissum") for the performance of studies evaluating the efficacy of its CBD-Loaded Liposome Platform Technology (LPT) in treating dogs. The Amendment...
2022-01-13 3:00 AM EST
Innocan Announces the Execution of a Research & License Agreement with Ramot, the Technology Transfer Company of the Tel Aviv University for Cannabinoids Loaded Exosome Delivery Platform (CLX)
Israel and Calgary, Alberta--(Newsfile Corp. - December 9, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce today that after the early substantial positive results of its CBD Loaded Exosome Platform (CLX), its Company's wholly-owned subsidiary, InnoCan Pharma Ltd. ("InnoCan Israel"), has signed a Research and License Agreement (the "New Agreement") with Ramot, the Technology Transfer Company of Tel Aviv University...
2021-12-09 3:00 AM EST
Innocan Pharma Announces the Successful Demonstration of Prolonged Release of CDB in Dogs Using Its LPT Technology
Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that in its recent study of its CBD-loaded liposome technology (LPT) on dogs, CBD showed prolonged plasma concentrations for at least six weeks after a single administration. These results are significant advance in the development of the technology demonstrating the advantages of LPT in dogs, which are good...
2021-11-18 4:00 PM EST
Innocan Pharma to Participate in the Lift & Co. Expo's Business Growth Panel on November 19th, 2021
Israel and Calgary, Alberta--(Newsfile Corp. - November 15, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce that CEO Iris Bincovich will be participating in the Industry Day Main Panel at the Lift & Co. Expo, on November 19, 2021, in Toronto. The panel, titled "Business Growth Update: Canadian Business for today's International Cannabis Marketplace", will include some of the world's leading companies in the nexus of...
2021-11-15 4:00 PM EST